Evidence map›Paper›PMID 24346422›Full record

ArticleClinical pharmacology and therapeutics2014

Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".

S M Markova, J B Schwartz, D L Kroetz

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

S M MarkovaDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
J B SchwartzDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
D L KroetzDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
University of California, San Francisco · US

Funding

PHARMACOGENETICS OF MEMBRANE TRANSPORTERSU01GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GIACOMINI, KATHLEEN M · 2000 to 2009
$29.2M
Pharmacogenomics of Membrane TransportersU19GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SALI, ANDREJ · 2010 to 2014
$16.3M
NIGMS NIH HHS GM061390
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Endothelin Receptor AntagonistsAryl Hydrocarbon HydroxylasesChemical and Drug Induced Liver InjuryFemaleHumansHypertension, PulmonaryMaleSulfonamidesAryl Hydrocarbon HydroxylasesEndothelin Receptor AntagonistsSulfonamides

Identifiers

PMID24346422
OpenAlexW1995680426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.